Cantor Fitzgerald Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Posted by Francis Steltz on Jul 6th, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price target dropped by equities research analysts at Cantor Fitzgerald from $785.00 to $750.00 in a report issued on Monday,Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 14.63% from the company’s previous close.

Other analysts also recently issued research reports about the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 24th. BMO Capital Markets decreased their target price on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. Piper Sandler dropped their price objective on shares of Regeneron Pharmaceuticals from $875.00 to $855.00 and set an “overweight” rating on the stock in a research note on Monday, May 18th. Barclays reduced their price target on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a report on Thursday, April 30th. Finally, Canaccord Genuity Group dropped their target price on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $790.48.

Get Our Latest Analysis on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $654.27 on Monday. The business’s fifty day simple moving average is $652.48 and its 200 day simple moving average is $725.31. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals has a 12 month low of $532.60 and a 12 month high of $821.11. The firm has a market capitalization of $69.17 billion, a P/E ratio of 15.94, a price-to-earnings-growth ratio of 1.44 and a beta of 0.24.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. During the same period last year, the firm posted $8.22 EPS. The business’s revenue was up 19.0% compared to the same quarter last year. As a group, analysts anticipate that Regeneron Pharmaceuticals will post 37.44 EPS for the current year.

Insiders Place Their Bets

In related news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the sale, the director owned 17,503 shares in the company, valued at approximately $12,343,815.72. The trade was a 0.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in REGN. WPG Advisers LLC grew its holdings in Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 25 shares during the period. SHP Wealth Management acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at about $26,000. Western Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals during the first quarter worth approximately $26,000. Titan Wealth CI Ltd acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $29,000. Finally, Board of the Pension Protection Fund purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $31,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

(Get Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.